The global intellectual property matters for Pfizer’s proposed adalimumab biosimilar has been solved with the signature of licensing agreements with AbbVie, which granted Pfizer a non-exclusive patent license for the use and sale of the product in many countries around the world. All litigation pending between the parties will be withdrawn. The financial details of the agreements have been kept confidential. According to the company, in US the license period will begin on November 20, 2023, while in Europe the launch of the new biosimilar may occur after its approval by the European Medicines Agency.